XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2022
Balance Sheet Components  
Balance Sheet Components

6. Balance Sheet Components

Property and Equipment, net

The Company’s property and equipment consisted of the following:

March 31, 

December 31, 

Useful Life

2022

    

2021

(in thousands)

Machinery and equipment

3-5 years

$

38,073

$

33,722

Computer equipment

3 years

4,893

 

4,893

Capitalized software held for internal use

3 years

3,112

2,395

Leasehold improvements

Lesser of useful life or lease term

26,647

 

13,640

Construction-in-process

28,051

 

30,279

100,776

 

84,929

Less: Accumulated depreciation and amortization

(22,415)

 

(19,413)

Total Property and Equipment, net

$

78,361

$

65,516

The Company’s long-lived assets are primarily located in the United States.

During the three months ended March 31, 2022, the increase in net property and equipment was due to purchases of new equipment for the Company’s laboratories located in Texas and California to expand testing capabilities, offset by depreciation expense of $3.0 million recorded in the three months ended March 31, 2022, compared to a depreciation expense of $2.5 million recorded in the three months ended March 31, 2021. The Company did not incur an impairment charge during the three months ended March 31, 2022.

Accrued Compensation

The Company’s accrued compensation consisted of the following:

March 31, 

    

December 31, 

2022

    

2021

(in thousands)

Accrued paid time off

$

2,809

$

2,567

Accrued commissions

 

12,305

 

15,726

Accrued bonuses

 

6,826

 

15,854

Other accrued compensation

 

10,456

 

6,794

Total accrued compensation

$

32,396

$

40,941

Other Accrued Liabilities

The Company’s other accrued liabilities consisted of the following:

March 31, 

    

December 31, 

2022

    

2021

(in thousands)

Reserves for refunds to insurance carriers

$

17,326

$

17,210

Accrued charges for third-party testing

5,445

5,849

Testing and laboratory materials from suppliers

5,561

3,799

Marketing and corporate affairs

7,563

7,853

Legal, audit and consulting fees

18,645

 

11,758

Accrued shipping charges

4,792

969

Sales tax payable

788

2,230

Accrued third-party service fees

14,483

13,442

Clinical trials and studies

 

17,835

11,218

Operating lease liabilities, current portion

5,239

5,752

Fixed asset purchases

5,370

1,853

Other accrued interest

2,695

1,078

Other accrued expenses

 

10,895

10,342

Total other accrued liabilities

$

116,637

$

93,353

 

Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers, and additional amounts that the Company estimates for potential refund requests during the period. When the Company releases these previously accrued amounts, they are recognized as product revenues in the condensed statements of operations and comprehensive loss.

The following table summarizes the reserve balance and activities for refunds to insurance carriers for the three months ended March 31, 2022 and 2021:

March 31, 

    

March 31, 

2022

    

2021

(in thousands)

Beginning balance

$

17,210

$

17,366

Additional reserves

 

3,502

 

5,594

Refunds to carriers

 

(1,991)

(1,403)

Reserves released to revenue

(1,395)

(1,253)

Ending balance

$

17,326

$

20,304